解毒降糖合剂对2型糖尿病患者炎性因子影响的观察

Observation on treating inflammatory cytokines of type 2 diabetic with the Jiedu Jiangtang Heji

目的:观察解毒降糖合剂对2型糖尿病患者的炎性因子(CRP、IL-6、TNF-α)的影响。方法:将确诊为2型糖尿病的患者60例随机分为治疗组和对照组,两组患者均采用治疗原则基本相同的基础治疗方法(包括饮食治疗、运动治疗等),在基础治疗的同时,治疗组口服吡格列酮15mg,1次/d,同时口服解毒降糖合剂,250m L/次,3次/d;对照组口服吡格列酮15mg,1次/d,4周为1个疗程,连服2个疗程。疗程结束后观察两组治疗前后中医临床症状积分、炎性因子及空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1C)及变化。结果:两组的中医临床症状积分、空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1C)及各炎性因子指标均有下降(P<0.05)。与对照组相比,治疗组治疗后中医临床症状积分及各炎性因子指标降低更显著,差异有显著性意义(P<0.01)。结论:2型糖尿病采用中医辨证与西医辨病相结合的治疗,采取清热解毒、补虚扶正方法施治,能更加有效地改善2型糖尿病患者的临床症状,减少炎性因子表达水平。

Objective： To observe the efficacy of treating inflammatory cytokines of type 2 diabetes with the Jiedu Jiangtang Heji admixture. Methods： 60 cases of type 2 diabetes were randomly divided into the treatment group and control group. Both groups were given basic treatment （including the diet and exercise therapy, etc.）; and pioglitazone. The treatment group was given the Jiedu Jiangtang Heji more.TCM clinical symptom score, inflammatory cytokines, FPG, 2HpG, HbA1C were observed before and after treatment. Results： After treatment, TCM clinical symptom score, inflammatory cytokines, FPG, 2HpG, HbA1C were decreased （P〈0.05）. TCM clinical symptom score and inflammatory cytokines index in the treatment group have a higher decreased than the control group. The difference was statistically significant （P〈0.01）. Conclusion： Treating type 2 diabetes in TCM differentiation could improve clinical symptoms, reduce level of inflammatory cytokines.